Market capitalization | $0.00 |
Enterprise Value | $-1.44m |
EV/FCF (TTM) EV/FCF | 0.03 |
Short interest | 8.92% |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Calithera Biosciences, Inc.:
1 Analyst has issued a forecast Calithera Biosciences, Inc.:
Dec '22 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.39 -1.39 |
117%
117%
|
|
EBITDA | -41 -41 |
64%
64%
|
EBIT (Operating Income) EBIT | -42 -42 |
63%
63%
|
Net Profit | -21 -21 |
82%
82%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Susan Molineaux |
Founded | 2010 |
Website | www.calithera.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.